An interventional study of Propylene Glycol, 0.6% eye drops and Preservative-free 0.9% Saline solution in Dry Eye, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-23.
Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Propylene Glycol in Dry Eye Syndromes — 3 open to participants now, 3 under way, none of them phase 3. Propylene Glycol · Dry Eye Syndromes.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, this one has the largest enrollment, is the only one that started in 2014, is one of 3 with no phase, and was the 4th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.
Browse Dry Eye Syndromes studies →3 of the 12 studies testing Propylene Glycol in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:
Andover Research Eye Institute · Sites in United States
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
National Taiwan University Hospital · Sites in Taiwan
Ages 20–85
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2014.
This study's enrollment of 279 is above the median of 60 across 1,129 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 87 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
92 studies in Dry Eye Syndromes by Alcon: 1 open now, 1 under way, none of them phase 3. Of 90 finished, 38 (42%) have results posted.
Among the 92 studies in Dry Eye Syndromes by Alcon, this one is the 13th largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2014, is one of 64 with no phase, and was the 62nd registered.
Alcon’s Dry Eye Syndromes studies by the year they started, since 2005.
1 of the studies testing Propylene Glycol in Dry Eye Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06763731National Taiwan University HospitalOptimizing the Ocular Surface With Systane COMPLETE in Patients With Dry Eye Planning for Cataract Surgery | 2027-01-14 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Propylene Glycol in Dry Eye Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 92 in Dry Eye Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the superior efficacy of Systane® Balance over Preservative-Free 0.9% Saline following 35 days of QID (4 times a day) dosing in treating dry eye subjects with lipid deficiency.
This study consisted of 4 visits conducted during 3 sequential phases: the Run-in Phase (which included a screening visit and run-in period), Treatment Phase I and Treatment Phase II. In Phase I, subjects were randomized to either Systane® Balance or Saline and dosed 4 times a day for 35 days. In Phase II (Day 35-90) subjects continued to dose with their assigned product on an as-needed basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have all of the following in at least 1 eye at Screening:
Exclusion Criteria:
Women of are excluded from participating in this study if they met any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
Drug: Propylene Glycol, 0.6% eye drops
Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
Drug: Preservative-free 0.9% Saline solution
Commercially available eye drops used during Treatment Phase
Also known as: Systane® Balance
Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
Change From Baseline in TFBUT at Day 35
TFBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using ophthalmic dye and a biomicroscope and measured in seconds. Subjects were dosed in the office 1 hour ±10 minutes prior to TFBUT assessment. A shorter TFBUT indicates a higher likelihood of dry eye symptoms. A positive change indicates an improvement in TFBUT. One eye (study eye) contributed to the analysis.
Time frame: Baseline (Day 0), Day 35
Change From Baseline in TOSS Score at Day 35
The TOSS score (a cumulative cornea and conjunctival staining score) was assessed by the investigator using ophthalmic dye and a biomicroscope. Three areas of the ocular surface were graded for dryness on a 0-5 scale (0=Absent, 5=Severe), with a resultant overall score of 0-15. A negative change indicates an improvement in dry eye-related staining. One eye (study eye) contributed to the analysis.
Time frame: Baseline (Day 0), Day 35
Change From Baseline in OSDI Score at Day 35
The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative change number represents a perceived improvement in ocular health.
Time frame: Baseline (Day 0), Day 35
Change From Baseline in IDEEL Treatment Effectiveness Score at Day 35
The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment effectiveness questions (Questions 2-5) using a 0-4 Likert-type scale, where 0=None of the time and 4=All of the time. The IDEEL treatment effectiveness score was calculated as the sum of the responses from Questions 2-5 divided by the number of questions (2-5) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.
Time frame: Baseline (Day 0), Day 35
Change From Baseline in IDEEL Treatment Inconvenience Score at Day 35
The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment inconvenience questions (Questions 6, 8-10) using a 0-4 Likert-type scale, where 0=All of the time and 4=None of the time. The IDEEL treatment inconvenience score was calculated as the sum of the responses from Questions 6, 8-10 divided by the number of questions (6, 8-10) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.
Time frame: Baseline (Day 0), Day 35
Subjects were recruited from 14 study centers located in France, 4 study centers located in Germany, 3 study centers located in Spain, 3 study centers located in the Netherlands, 4 study centers located in the UK, 4 study centers located in Italy, and 3 study centers located in Poland.
| Milestone | Systane Balance | Saline |
|---|---|---|
| Started | 112 | 102 |
| Completed | 99 | 82 |
| Not completed | 13 | 20 |
| Withdrew: Adverse event | 5 | 2 |
| Withdrew: Lack of efficacy | 1 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Non-compliance with study drug | 0 | 3 |
| Withdrew: Other | 4 | 5 |
TFBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using ophthalmic dye and a biomicroscope and measured in seconds. Subjects were dosed in the office 1 hour ±10 minutes prior to TFBUT assessment. A shorter TFBUT indicates a higher likelihood of dry eye symptoms. A positive change indicates an improvement in TFBUT. One eye (study eye) contributed to the analysis.
| seconds | Systane Balance | Saline |
|---|---|---|
| Change From Baseline in TFBUT at Day 35 | 1.5 ± 0.2 | 0.5 ± 0.2 |
The TOSS score (a cumulative cornea and conjunctival staining score) was assessed by the investigator using ophthalmic dye and a biomicroscope. Three areas of the ocular surface were graded for dryness on a 0-5 scale (0=Absent, 5=Severe), with a resultant overall score of 0-15. A negative change indicates an improvement in dry eye-related staining. One eye (study eye) contributed to the analysis.
| units on a scale | Systane Balance | Saline |
|---|---|---|
| Change From Baseline in TOSS Score at Day 35 | -0.81 ± 0.14 | -0.64 ± 0.15 |
The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative change number represents a perceived improvement in ocular health.
| units on a scale | Systane Balance | Saline |
|---|---|---|
| Change From Baseline in OSDI Score at Day 35 | -13.7 ± 1.44 | -8.38 ± 1.56 |
The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment effectiveness questions (Questions 2-5) using a 0-4 Likert-type scale, where 0=None of the time and 4=All of the time. The IDEEL treatment effectiveness score was calculated as the sum of the responses from Questions 2-5 divided by the number of questions (2-5) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.
| units on a scale | Systane Balance | Saline |
|---|---|---|
| Change From Baseline in IDEEL Treatment Effectiveness Score at Day 35 | 21.51 ± 2.43 | 5.50 ± 2.65 |
The IDEEL is a 10-item questionnaire designed to assess the subject's general satisfaction with treatment use. The subject responded to treatment inconvenience questions (Questions 6, 8-10) using a 0-4 Likert-type scale, where 0=All of the time and 4=None of the time. The IDEEL treatment inconvenience score was calculated as the sum of the responses from Questions 6, 8-10 divided by the number of questions (6, 8-10) answered, multiplied by 25, for a resultant overall score of 0-100. A positive change number represents perceived improvement.
| units on a scale | Systane Balance | Saline |
|---|---|---|
| Change From Baseline in IDEEL Treatment Inconvenience Score at Day 35 | 1.30 ± 1.56 | 0.77 ± 1.70 |
Collected over Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 90 days). AEs were reported as pretreatment and treatment-emergent. Ocular adverse events are presented for both study eye and non-study eye.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pretreatment | — | 0/279 (0%) | 0/279 (0%) |
| Systane Balance | — | 2/110 (1.8%) | 6/110 (5.5%) |
| Saline | — | 2/100 (2%) | 1/100 (1%) |
| Event | Pretreatment | Systane Balance | Saline |
|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/279 | 0/110 | 1/100 |
| Renal cyst excisionSurgical and medical procedures | 0/279 | 0/110 | 1/100 |
| Arterial haemorrhageVascular disorders | 0/279 | 0/110 | 1/100 |
| Multiple fracturesInjury, poisoning and procedural complications | 0/279 | 1/110 | 0/100 |
| Laryngeal operationSurgical and medical procedures | 0/279 | 1/110 | 0/100 |
| Event | Pretreatment | Systane Balance | Saline |
|---|---|---|---|
| Eye irritationEye disorders | 0/279 | 6/110 | 1/100 |
This analysis population includes all randomized subjects.
| Age, Continuous(years) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 59.5 ± 15.5 | 58.4 ± 14.0 | 59.0 ± 14.7 |
| Sex: Female, Male(Participants) | Systane Balance | Saline | Total |
|---|---|---|---|
| Female | 91 | 72 | 163 |
| Male | 21 | 30 | 51 |
| Tear Film Break-up Time (TFBUT)(seconds) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 3.73 ± 1.37 | 3.71 ± 1.59 | 3.72 ± 1.48 |
| Total Ocular Surface Staining (TOSS) Score(units on a scale) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 3.45 ± 2.14 | 3.35 ± 2.38 | 3.40 ± 2.25 |
| Ocular surface disease index (OSDI)(units on a scale) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 40.24 ± 17.48 | 38.27 ± 17.39 | 39.30 ± 17.42 |
| Impact of Dry Eye on Everyday Life (IDEEL) Treatment Effectiveness Score(units on a scale) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 44.63 ± 27.32 | 46.15 ± 27.86 | 45.35 ± 27.52 |
| IDEEL Treatment Inconvenience(units on a scale) | Systane Balance | Saline | Total |
|---|---|---|---|
| Mean | 76.61 ± 22.08 | 74.48 ± 24.85 | 75.60 ± 23.40 |
No study locations are listed for this record.
The record gives a start of Feb 2014, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propylene Glycol